Eurofins Acquires the Discovery and Development Solutions Business of Merck KGaA - - BioPharm International

ADVERTISEMENT

Eurofins Acquires the Discovery and Development Solutions Business of Merck KGaA



Eurofins Scientific has signed an agreement to acquire the assets of the Discovery and Development Solutions (DDS) business of Merck Millipore (EMD Millipore in the United States and Canada), the Life Science division of Merck KGaA, Darmstadt, Germany. DDS is a provider of bioanalytical testing and early stage discovery services and products to the biopharmaceutical market. DDS generates revenues of about $35 million with 175 employees from its three sites in Missouri, Scotland, and England.

In addition, DDS provides expertise in bioanalytical testing to support clinical trials. The acquisition of DDS will strengthen Eurofins' presence in the early stage discovery solutions market while adding expertise in high-quality bioanalytical services, according to the company. After the transaction, DDS will continue to provide products and services to Merck KGaA's pharma business.

As part of the agreement, DDS will continue to be led by Christina Shasserre, who has headed the DDS business since 2010. Shasserre will become president of Eurofins Pharma BioAnalytical Services, as the company will be renamed following the closing. The transaction is subject to standard closing conditions, which the parties expect to complete within 90 days.

Source: Eurofins Scientific
blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines

Click here